A weekly 2.0mg somaglutide significantly reduces HbA1c in people with type 2 diabetes

On November 17th Noor and Nord announced the main results of the SUSTAIN FORTE trial, a 40-week phase 3b clinical trial in 961 patients with type 2 diabetes who required intensive treatment, to analyze the efficacy and safety of receiving 2.0 mg and 1.0 mg of semalutide as a drug-assisted treatment of metformin and/or sulfonamide.
results showed that at the 40th week, 2.0 mg somaglutide significantly reduced glycation hemoglobin (HbA1c) compared to a weekly treatment of 1.0 mg somaglupeptide, reaching the main endpoint of the trial.
in assessing the expected therapeutic effect (everyone adhered to treatment and did not start other type 2 diabetes treatments),
found that, on a higher HbA1c average baseline of 8.9 per cent, patients treated with 2.0 mg of somalutide had a 2.2 per cent reduction in HbA1c;
The American Diabetes Association (ADA) set the treatment target at HbA1c below 7.0 percent, with 68 percent of patients in the Somaglutide 2.0 mg group and 58 percent in the 1.0 mg group.
addition, from the average weight baseline of 99.3 kg, patients in the 2.0 mg Somaglutide group lost 6.9 kg, compared with 6.0 kg in the 1.0 mg group, which was also statistically significant.
Analysis of the estimated therapeutic policy (i.e., whether the treatment effect was adhered to or whether other type 2 diabetes treatments were adhered to or not) found that HbA1c in patients in the 2.0 mg Somaglutide treatment group decreased by 2.1%, compared with a 1.9% decrease in HbA1c in patients in the 1.0 mg group.
2.0 mg group lost 6.4 kg, compared with 5.6 kg in the 1.0 mg group, but there was no statistical significance.
test data showed that both doses of somaglutide were safe and well-to-bear.
most common adverse reactions are gastrointestinal diseases, the vast majority of which are mild to moderate and gradually decrease over time, consistent with the GLP-1-1-subjected agitant class.
2.0 mg of somalutide had similar gastrointestinal adverse reactions compared to the 1.0 mg dose, with nausea rates of about 15% in both doses.
the treatment interruption rate caused by adverse events in both doses was similar, at less than 5%.
it is understood that the SUSTAIN trial program is an ongoing clinical development program for weekly off-the-skin injections of somaglutide injections, consisting of 11 Phase 3 global clinical trials, including trials of cardiovascular outcomes, in more than 11,000 adults with type 2 diabetes.
somatroptide 1.0 mg injection (trade name Ozempic) was approved in the United States in 2017 for the treatment of type 2 diabetes, and its oral preparation (trade name Rybelsus) was approved in 2019, becoming the first U.S.-approved treatment for glutatrogytin-like peptide (GLP-1) that does not require injection.
source: Once-weekly semaglutide 2.0 mg proves superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial Original title: No and Nord weekly slutgide 2.0 mg can significantly reduce type 2 diabetics glycoglobin